Highlights

  • Imricor (ASX:IMR) launched a combined interventional MR (iMR) lab solution with Philips for cardiac procedures.
  • The solution integrates Philips’ 1.5T BlueSeal helium-free MR platform with Imricor’s MR-compatible systems and tools.
  • The initial configuration supports MR-guided cardiac interventions, including electrophysiology procedures.
  • The commercial solution is immediately available in CE-marked markets, with selected US configurations available.
  • Imricor traded at AUD 2.02, up 4.66% during the morning session on 28 August 2026.

Imricor Medical Systems, Inc. (ASX:IMR) has announced the commercial launch of a new interventional MR (iMR) lab solution developed in collaboration with Royal Philips, combining imaging technology and MR-compatible interventional systems for cardiac procedures. The company said the collaboration advances its efforts to support MR-guided cardiac interventions through an integrated clinical solution.

During the morning session on 28 August 2026, Imricor (ASX:IMR) was trading at AUD 2.02, up 4.66%. The stock remains up 45.32% over the past year, based on the provided market information.

Technology Launch

The newly launched iMR lab solution combines Philips’ 1.5 Tesla (1.5T) MRI platform and interventional workflow capabilities with Imricor’s portfolio of MR-compatible systems and consumables. The first commercially available configuration has been designed to support iMR-guided workflows for cardiac interventions, including cardiac electrophysiology procedures.

The combined offering brings together Philips’ 1.5T BlueSeal helium-free MR platform with Imricor’s NorthStar® Mapping System, Advantage-MR® EP Recorder/Stimulator and other Capital systems, alongside single-use catheters and interventional tools.

Imricor said the solution provides a purpose-built environment designed to enable MR-based visualisation and guidance during cardiac interventions.

Commercial Availability

The initial configuration is commercially available immediately in CE-marked markets, while selected US configurations are currently available. Further US configurations are expected to become available subject to regulatory clearances.

The solution will also be showcased at ESC Congress 2026 in Munich.

Imricor stated that the collaboration creates a broader commercial platform that may support expansion into additional iMR-guided procedures, subject to clinical, regulatory and commercial development.

Partnership Development

The launch follows Philips’ Third Party Declaration of Compatibility announced earlier in August 2026 and represents a further step in the Philips-Imricor relationship, which has developed since 2012 from joint technology development into the commercial launch of an integrated iMR lab solution.

Imricor Chair, President and CEO Steve Wedan said the collaboration reflects the company’s objective of bringing MR imaging into the procedure room rather than moving procedures into diagnostic MRI suites. He said combining Philips’ MR platform with Imricor’s iMR systems and interventional tools creates a high-performance iMR lab solution.

Market Expansion

The company’s technology platform is focused on enabling interventional procedures under real-time magnetic resonance guidance rather than traditional X-ray fluoroscopy guidance. Imricor develops MR-compatible products for iMR procedures, including capital equipment and single-use devices such as ablation catheters, diagnostic catheters, steerable sheaths and other tools used in an iMR lab.

Imricor said its products are approved in the European Union, the Kingdom of Saudi Arabia and New Zealand, while NorthStar and Vision-MR Diagnostic Catheter are cleared in the United States.

The company said the collaboration with Philips positions Imricor’s technology within a combined solution alongside a global provider of MR imaging systems.

Investor Takeaway

Imricor’s latest update highlights the commercial launch of an integrated iMR solution with Philips, bringing together MRI technology, interventional systems and cardiac procedure capabilities. Investors may continue watching commercial adoption, regulatory progress across additional markets and further development of the company’s MR-guided intervention platform.